NCT06910098已完成不适用
Assessment of Impact of Rosuvastatin Doses on Low Density Lipoprotein Levels, Creatinine Phosphokinase Levels and Aspartate Aminotransferase Levels: A Randomized Controlled Trail
Central Park Medical College1 个研究点 分布在 1 个国家目标入组 195 人开始时间: 2023年12月1日最近更新:
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 195
- 试验地点
- 1
- 主要终点
- impact of rosuvstatin over LDL, CPK and AST levels
研究概览
简要总结
Particpants were divided into groups based on doses of rosuvastatin and were assessed and for CPK, LDL and AST levels
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 30 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •patients who were already on statins
排除标准
- •hereditary diseases including familial hypercholesterolemia and kidney diseases
研究组 & 干预措施
Group 1
Experimental
receiving drug dose of 5mg
干预措施: Rosuvastatin (Drug)
Group 2
Active Comparator
receiving grug dose of 10 mg
干预措施: Rosuvastatin (Drug)
Group 3
Active Comparator
receiving dose of 20 mg
干预措施: Rosuvastatin (Drug)
结局指标
主要结局
impact of rosuvstatin over LDL, CPK and AST levels
时间窗: 12 weeks
Pre- and post-intervention levels of Aspartate Aminotransferase (AST) in U/L were recorded and were compared in all study groups for assessment of the impact of various doses of rosuvastatin in terms of liver damage.
次要结局
未报告次要终点
研究者
Mirza Zeeshan Sikandar
Dr
Central Park Medical College
研究点 (1)
Loading locations...
相似试验
终止
2 期
Effect of Rosuvastatin on Endothelial FunctionCardiovascular DiseaseHIV InfectionsNCT00986999University of Hawaii7
已完成
不适用
Efficacy of Low-dose (10 mg) Rosuvastatin in Korean 4 Statin Benefit Groups Per 2013 ACC/AHA GuidelineDyslipidemiasNCT03903029Seoul National University Hospital242
已完成
3 期
A Study to Investigate the Effect of Rosuvastatin (CRESTOR®) on High Density Lipoprotein Kinetics in Patients With the Metabolic SyndromeMetabolic SyndromeDyslipidemiaNCT00240305AstraZeneca15
招募中
4 期
Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy in Patients With Minimal to Intermediate Coronary Artery Disease Without Percutaneous Coronary InterventionDyslipidemiasPrimary PreventionCoronary Artery DiseaseNCT06186037Saint Vincent's Hospital, Korea6,356
已完成
3 期
Study of High Density Lipoprotein Cholesterol (HDL-C)-Raising Mechanism of Rosuvastatin (CRESTOR™) by Quantifying the Key Steps of Reverse Cholesterol Transport (RCT)Metabolic SyndromeDyslipidemiaNCT00240266AstraZeneca15